{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:13:54Z","timestamp":1792602834717,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["BC011525"],"award-info":[{"award-number":["BC011525"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["2014194"],"award-info":[{"award-number":["2014194"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005345","name":"American Association for Dental, Oral, and Craniofacial Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.phrs.2022.106162","type":"journal-article","created":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T02:07:17Z","timestamp":1646446037000},"page":"106162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"special_numbering":"C","title":["Cell cycle checkpoints and beyond: Exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor\u2013resistant cancer"],"prefix":"10.1016","volume":"178","author":[{"given":"Nitasha","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachi","family":"Horibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2022.106162_bib1","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib2","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2022.106162_bib3","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106162_bib4","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106162_bib6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic","volume":"381","author":"Golan","year":"2019","journal-title":"Cancer N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106162_bib8","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106162_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4986365","article-title":"BRCA mutations in prostate cancer: prognostic and predictive implications","volume":"2020","author":"Messina","year":"2020","journal-title":"J. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phrs.2022.106162_bib11","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3390\/cancers12061607","article-title":"Overcoming platinum and PARP-inhibitor resistance in ovarian cancer","volume":"12","author":"McMullen","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2022.106162_bib12","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrc3916","article-title":"Replication stress and cancer","volume":"15","author":"Gaillard","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2022.106162_bib13","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ccell.2019.03.013","article-title":"Capitalizing on cancer replication stress by preventing PAR chain turnover: a new type of synthetic lethality","volume":"35","author":"McDermott","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2022.106162_bib14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.phrs.2022.106162_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-020-00874-6","article-title":"Participation of the ATR\/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer","volume":"13","author":"Gralewska","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib16","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.molcel.2020.04.035","article-title":"Biomarker-guided development of DNA repair inhibitors","volume":"78","author":"Cleary","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2022.106162_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.09.003","article-title":"Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition","volume":"71","author":"Haynes","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2022.106162_bib18","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016600","article-title":"Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins","volume":"7","author":"Prakash","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.phrs.2022.106162_bib19","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.molcel.2016.12.007","article-title":"Coupling of homologous recombination and the checkpoint by ATR","volume":"65","author":"Buisson","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2022.106162_bib20","doi-asserted-by":"crossref","first-page":"zcaa006","DOI":"10.1093\/narcan\/zcaa006","article-title":"Intrinsic ATR signaling shapes DNA end resection and suppresses toxic DNA-PKcs signaling","volume":"2","author":"Dibitetto","year":"2020","journal-title":"NAR Cancer"},{"key":"10.1016\/j.phrs.2022.106162_bib21","doi-asserted-by":"crossref","first-page":"8311","DOI":"10.1093\/nar\/gky625","article-title":"ATR-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells","volume":"46","author":"Kim","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2022.106162_bib22","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.cub.2013.06.063","article-title":"Chk1 inhibits E2F6 repressor function in response to replication stress to maintain cell-cycle transcription","volume":"23","author":"Bertoli","year":"2013","journal-title":"Curr. Biol."},{"key":"10.1016\/j.phrs.2022.106162_bib23","doi-asserted-by":"crossref","first-page":"7554","DOI":"10.1093\/nar\/gkab584","article-title":"PARP1 and CHK1 coordinate PLK1 enzymatic activity during the DNA damage response to promote homologous recombination-mediated repair","volume":"49","author":"Peng","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2022.106162_bib24","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3390\/cancers13040795","article-title":"Clinical candidates targeting the ATR\u2013CHK1\u2013WEE1 axis in cancer","volume":"13","author":"Gorecki","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2022.106162_bib25","doi-asserted-by":"crossref","first-page":"13072","DOI":"10.18632\/oncotarget.3865","article-title":"Wee1 is required to sustain ATR\/Chk1 signaling upon replicative stress","volume":"6","author":"Saini","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2022.106162_bib26","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1038\/onc.2014.276","article-title":"ATR inhibition preferentially targets homologous recombination-deficient tumor cells","volume":"34","author":"Krajewska","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2022.106162_bib27","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1158\/1078-0432.CCR-19-0448","article-title":"The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition","volume":"25","author":"Parmar","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2022.106162_bib28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.gde.2021.07.003","article-title":"An extending ATR-CHK1 circuitry: the replication stress response and beyond","volume":"71","author":"Simoneau","year":"2021","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.phrs.2022.106162_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev-genet-121415-121658","article-title":"Functions, regulation, and therapeutic implications of the ATR checkpoint pathway","volume":"50","author":"Yazinski","year":"2016","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.phrs.2022.106162_bib30","doi-asserted-by":"crossref","first-page":"10779","DOI":"10.1074\/jbc.M116.772475","article-title":"DNA-damage-induced degradation of EXO1 exonuclease limits DNA end resection to ensure accurate DNA repair","volume":"292","author":"Tomimatsu","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2022.106162_bib31","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.molcel.2019.04.003","article-title":"Ca(2+)-stimulated AMPK-dependent phosphorylation of Exo1 protects stressed replication forks from aberrant resection","volume":"74","author":"Li","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2022.106162_bib32","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1101\/gad.214080.113","article-title":"ATR phosphorylates SMARCAL1 to prevent replication fork collapse","volume":"27","author":"Couch","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.phrs.2022.106162_bib33","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.molcel.2013.07.023","article-title":"FANCD2 binds MCM proteins and controls replisome function upon activation of s phase checkpoint signaling","volume":"51","author":"Lossaint","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2022.106162_bib34","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.celrep.2015.12.093","article-title":"Signaling from Mus81-Eme2-dependent DNA damage elicited by Chk1 deficiency modulates replication fork speed and origin usage","volume":"14","author":"Techer","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2022.106162_bib35","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-020-00959-2","article-title":"family business: regulation of mitosis, cancer progression, and therapeutic target","volume":"13","author":"Ghelli Luserna di Rora","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1747-1028-6-21","article-title":"Novel insights into maintaining genomic integrity: Wee1 regulating Mus81\/Eme1","volume":"6","author":"Martin","year":"2011","journal-title":"Cell Div."},{"key":"10.1016\/j.phrs.2022.106162_bib37","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1128\/MCB.00412-12","article-title":"Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption","volume":"32","author":"Beck","year":"2012","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2022.106162_bib38","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","article-title":"Targeting the ATR\/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models","volume":"23","author":"Kim","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2022.106162_bib39","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2022.106162_bib40","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/0008-5472.CAN-14-2593","article-title":"A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance","volume":"75","author":"Ceccaldi","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2022.106162_bib41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature14328","article-title":"REV7 counteracts DNA double-strand break resection and affects PARP inhibition","volume":"521","author":"Xu","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2022.106162_bib42","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/cas.12390","article-title":"Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells","volume":"105","author":"Niimi","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.phrs.2022.106162_bib43","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1038\/s41467-019-10993-5","article-title":"Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma","volume":"10","author":"Ning","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2022.106162_bib44","doi-asserted-by":"crossref","first-page":"76534","DOI":"10.18632\/oncotarget.12266","article-title":"Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition","volume":"7","author":"Murai","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2022.106162_bib45","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.molcel.2018.01.012","article-title":"SLFN11 blocks stressed replication forks independently of ATR","volume":"69","author":"Murai","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2022.106162_bib46","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/1878-0261.12573","article-title":"Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells","volume":"13","author":"Schoonen","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib47","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2022.106162_bib48","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2020.10.029","article-title":"Advanced prostate cancer with ATM loss: PARP and ATR inhibitors","volume":"79","author":"Neeb","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.phrs.2022.106162_bib49","doi-asserted-by":"crossref","first-page":"111026","DOI":"10.18632\/oncotarget.22195","article-title":"Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer","volume":"8","author":"Brill","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2022.106162_bib50","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1158\/1078-0432.CCR-14-1038","article-title":"Combined inhibition of Wee1 and PARP1\/2 for radiosensitization in pancreatic cancer","volume":"20","author":"Karnak","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2022.106162_bib51","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/1541-7786.MCR-17-0455","article-title":"PARP1 trapping and DNA replication stress enhance radiosensitization with combined WEE1 and PARP Inhibitors","volume":"16","author":"Parsels","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.phrs.2022.106162_bib52","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.ccell.2019.05.001","article-title":"Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy","volume":"35","author":"Fang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2022.106162_bib53","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.neo.2018.03.003","article-title":"Combined inhibition of ATR and WEE1 as a novel therapeutic strategy in triple-negative breast cancer","volume":"20","author":"Jin","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.phrs.2022.106162_bib54","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2022.106162_bib55","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1038\/s41388-020-1383-4","article-title":"Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer","volume":"39","author":"Nair","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2022.106162_bib56","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1158\/0008-5472.CAN-13-3369","article-title":"ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses","volume":"74","author":"Josse","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2022.106162_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107450","article-title":"Targeting ATR as cancer therapy: a new era for synthetic lethality and synergistic combinations?","volume":"207","author":"Bradbury","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2022.106162_bib58","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2022.106162_bib59","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s41416-018-0017-x","article-title":"From checkpoint to checkpoint: DNA damage ATR\/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation","volume":"118","author":"Mouw","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2022.106162_bib60","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.trecan.2021.06.002","article-title":"Targeting the replication stress response through synthetic lethal strategies in cancer medicine","volume":"7","author":"Ngoi","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.phrs.2022.106162_bib61","first-page":"1307","article-title":"Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing","volume":"8","author":"Sun","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.phrs.2022.106162_bib62","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.jtho.2019.08.009","article-title":"Combination treatment of the oral CHK1 inhibitor, SRA737, anD Low-dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 blockade by modulating the immune microenvironment in SCLC","volume":"14","author":"Sen","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib63","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4143\/crt.2019.183","article-title":"Therapeutic Co-targeting of WEE1 and ATM downregulates PD-L1 expression in pancreatic cancer","volume":"52","author":"Jin","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2022.106162_bib64","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1158\/0008-5472.CAN-20-1439","article-title":"Targeting the PI3K\/mTOR pathway augments CHK1 inhibitor-induced replication stress and antitumor activity in high-grade serous ovarian cancer","volume":"80","author":"Huang","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2022.106162_bib65","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/cancers12071726","article-title":"Cotargeting CHK1 and PI3K synergistically suppresses tumor growth of oral cavity squamous cell carcinoma in patient-derived xenografts","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2022.106162_bib66","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib67","first-page":"16","volume":"12","author":"Dillon","year":"2018","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib68","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib69","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Disco"},{"key":"10.1016\/j.phrs.2022.106162_bib70","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.6038","article-title":"Prexasertib, a cell cycle checkpoint kinase 1 inhibitor, in BRCA mutant recurrent high-grade serous ovarian cancer (HGSOC): a proof-of-concept single arm phase II study","volume":"38","author":"Lampert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib71","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(18)30009-3","article-title":"Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study","volume":"19","author":"Lee","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib72","doi-asserted-by":"crossref","first-page":"CT012","DOI":"10.1158\/1538-7445.AM2019-CT012","article-title":"Abstract CT012: open-label, multicenter, phase Ib study to assess safety, tolerability and efficacy of adavosertib monotherapy in patients with advanced solid tumors: expansion cohorts","volume":"79","author":"Bauer","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2022.106162_bib73","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1200\/JCO.2021.39.15_suppl.5516","article-title":"Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer","volume":"39","author":"Wethington","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib74","doi-asserted-by":"crossref","first-page":"A080","DOI":"10.1158\/1535-7163.TARG-19-A080","article-title":"Abstract A080: olaparib and the ATR inhibitor AZD6738 in relapsed, refractory cancer patients with homologous recombination (HR) repair mutations \u2013 OLAPCO","volume":"18","author":"Eder","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2022.106162_bib75","doi-asserted-by":"crossref","first-page":"v159","DOI":"10.1093\/annonc\/mdz244.012","article-title":"450PDA phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT part A, B)","volume":"30","author":"Dillon","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib76","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1158\/1078-0432.CCR-21-1279","article-title":"Phase 1 combination study of the CHK1 inhibitor prexasertib and the PARP inhibitor olaparib in high-grade serous ovarian cancer and other solid tumors","volume":"27","author":"Do","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2022.106162_bib77","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.2021.39.15_suppl.5505","article-title":"EFFORT: efficacy of adavosertib in parp resistance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer","volume":"39","author":"Westin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib78","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41523-020-00181-w","article-title":"Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer","volume":"6","author":"Guerrero Llobet","year":"2020","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.phrs.2022.106162_bib79","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41416-021-01406-w","article-title":"Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours","volume":"125","author":"Shapiro","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2022.106162_bib80","doi-asserted-by":"crossref","first-page":"TPS5597","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS5597","article-title":"A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer","volume":"38","author":"Choudhury","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib81","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1200\/JCO.2016.34.15_suppl.2513","article-title":"Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792)","volume":"34","author":"Plummer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib82","doi-asserted-by":"crossref","first-page":"v431","DOI":"10.1093\/annonc\/mdz250.068","article-title":"1060TiP - randomized, phase Ib\/II study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer","volume":"30","author":"Banerjee","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib83","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1158\/1078-0432.CCR-20-3242","article-title":"Preclinical evaluation and phase Ib study of prexasertib, a CHK1 inhibitor, and samotolisib (LY3023414), a dual PI3K\/mTOR inhibitor","volume":"27","author":"Hong","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2022.106162_bib84","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1200\/JCO.2014.57.5027","article-title":"Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 As monotherapy and in combination with gemcitabine in patients with advanced solid tumors","volume":"33","author":"Daud","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib85","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/annonc\/mdy076","article-title":"Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors","volume":"29","author":"Italiano","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2022.106162_bib86","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/13543784.2019.1694661","article-title":"Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer","volume":"28","author":"Dent","year":"2019","journal-title":"Expert Opin. Investig. Drugs"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822001074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822001074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:31:25Z","timestamp":1760913085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822001074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":86,"alternative-id":["S1043661822001074"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106162","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell cycle checkpoints and beyond: Exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor\u2013resistant cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106162","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106162"}}